Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839988 | 0.88 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL839989 | 0.88 | CYP3A4 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL29288420 | 0.87 | PTPRA (0.37) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL18302874 | 0.87 | PTPRA (0.37) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL19978990 | 0.85 | CYP3A4 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2PPARA | |
| SCHEMBL839957 | 0.83 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL839958 | 0.83 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL838730 | 0.81 | RAB9A (0.40) | SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL838731 | 0.81 | RAB9A (0.40) | SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL13311307 | 0.80 | SMYD2 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | CYP3A4 1716/4885HTT 2010/4885SMN1; SMN2 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.